Close
Almac
Achema middle east

KCCI seeks leniency for pharma industry

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Sanofi to Buy Vaccine Developer Dynavax in a $2.5b Deal

The French pharma giant, Sanofi, has started a $15.50...

AstraZeneca Commits $100mn for Pan-KRAS Inhibitor by Jacobio

AstraZeneca has gone ahead and committed $100 million to...

Laboratory Equipment Outsourcing Through CDMOs: Strategic and Cost Implications

Outsourcing laboratory infrastructure to CDMOs offers pharma companies critical agility, transforming fixed capital costs into flexible operational expenses while accessing cutting-edge technology like Cryo-EM.
- Advertisement -

The Karachi Chamber of Commerce & Industry (KCCI) has expressed discontentment on alleged closure of pharmaceutical industry in the city in the wake of deaths in PIC Lahore due to drug reaction.

In a statement issued here Wednesday, KCCI President Mian Abrar Ahmad said that due to the closure of alleged industry since 1st February 2012, its exports are hampered besides leaving over 500 people particularly female staff unemployed. He urged the government to give fair chances to the owners of the alleged pharma company to clarify their position and allow them to carry internal audit and investigation.

Mian Abrar articulated that such incidents of drug reactions had happened in the developed countries which caused several deaths. Likewise tragedies happen, however, nowhere in the world such penal actions are taken to forcefully close down the industry. It is general practice worldwide to impose fines and penalties rather victimizing and forceful closure, he added

Latest stories

Related stories

Sanofi to Buy Vaccine Developer Dynavax in a $2.5b Deal

The French pharma giant, Sanofi, has started a $15.50...

AstraZeneca Commits $100mn for Pan-KRAS Inhibitor by Jacobio

AstraZeneca has gone ahead and committed $100 million to...

Laboratory Equipment Outsourcing Through CDMOs: Strategic and Cost Implications

Outsourcing laboratory infrastructure to CDMOs offers pharma companies critical agility, transforming fixed capital costs into flexible operational expenses while accessing cutting-edge technology like Cryo-EM.

Samsung Biologics to Buy US Drug Plant from GSK for $280M

On December 22, 2025, the news has been confirmed...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »